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Epithelial-to-mesenchymal transition (EMT) and its reversed process mesenchymal-to-
epithelial transition (MET) play a critical role in epithelial plasticity during development
and cancer progression. Among important regulators of these cellular processes are
non-coding RNAs (ncRNAs). The imprinted DLK1-DIO3 locus, containing numerous
maternally expressed ncRNAs including the lncRNA maternally expressed gene 3
(MEG3) and a cluster of over 50 miRNAs, has been shown to be a modulator of
stemness in embryonic stem cells and in cancer progression, potentially through the
tumor suppressor role of MEG3. In this study we analyzed the expression pattern and
functional role of ncRNAs from the DLK1-DIO3 locus in epithelial plasticity of the breast.
We studied their expression in various cell types of breast tissue and revisit the role
of the locus in EMT/MET using a breast epithelial progenitor cell line (D492) and its
isogenic mesenchymal derivative (D492M). Marked upregulation of ncRNAs from the
DLK1-DIO3 locus was seen after EMT induction in two cell line models of EMT. In
addition, the expression of MEG3 and the maternally expressed ncRNAs was higher in
stromal cells compared to epithelial cell types in primary breast tissue. We also show that
expression of MEG3 is concomitant with the expression of the ncRNAs from the DLK1-
DIO3 locus and its expression is therefore likely indicative of activation of all ncRNAs
at the locus. MEG3 expression is correlated with stromal markers in normal tissue
and breast cancer tissue and negatively correlated with the survival of breast cancer
patients in two different cohorts. Overexpression of MEG3 using CRISPR activation in a
breast epithelial cell line induced partial EMT and enriched for a basal-like phenotype.
Conversely, knock down of MEG3 using CRISPR inhibition in a mesenchymal cell line
reduced the mesenchymal and basal-like phenotype of the cell line. In summary our
study shows that maternally expressed ncRNAs are markers of EMT and suggests that
MEG3 is a novel regulator of EMT/MET in breast tissue. Nevertheless, further studies
are needed to fully dissect the molecular pathways influenced by non-coding RNAs at
the DLK1-DIO3 locus in breast tissue.
Keywords: DLK1-DIO3 locus, MEG3, ncRNAs, epithelial plasticity, breast progenitor cells
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INTRODUCTION
Breast cancer is the most common cancer in women and the
second most common cancer overall (Ghoncheh et al., 2016).
Despite major advances in diagnosis and treatment of cancer
in recent years, metastasis and development of resistance to
cancer therapies continues to be a challenge, causing over 90%
of all cancer-related deaths (Ben-Jacob et al., 2012). A major
contributing factor to metastasis and drug resistance is the
heterogeneity and plasticity of the cells within tumors (Dagogo-
Jack and Shaw, 2018). Epithelial-to-mesenchymal transition
(EMT), is a developmental process that can be hijacked by
cancer cells (Zeisberg and Kalluri, 2004; Moustakas and Heldin,
2007; Radisky et al., 2007). Generally, cells undergoing EMT,
acquire increased migration and invasive properties and show
increased resistance to apoptosis (Robson et al., 2006; Cao et al.,
2016). Through these processes, EMT is considered a major
mediator of phenotypic plasticity in cancer cells, metastatic
formation and drug resistance (Mani et al., 2008; Scheel and
Weinberg, 2012; Ansieau, 2013; Nieto et al., 2016; Lu and
Kang, 2019). Recently, hybrid E/M (or partial EMT) cells
have been shown to have even more metastatic and stem
cell potential compared to the full epithelial or mesenchymal
phenotype (Pastushenko et al., 2018). A reversed program,
mesenchymal-to–epithelial transition (MET) is considered to
facilitate colonization in secondary sites and reverse the plastic
mesenchymal phenotype back to an epithelial state (Lu and
Kang, 2019). This, however, is debated and further studies will
increase our knowledge of the role of EMT/MET in cancer
progression and metastasis.
EMT can be initiated through intrinsic factors such as
expression of EMT related transcription factors (SNAI1,
SNAI2, TWIST1, ZEB1, or ZEB2), cadherin switch from
E-cadherin (CDH1) to N-cadherin (CDH2) or through
epigenetic mechanisms. It can also be brought on by extrinsic
factors derived from the microenvironment, such as secreted
soluble factors: transforming growth factor-β (TGF-β), epidermal
growth factor (EGF), fibroblast growth factors (FGFs), hepatocyte
growth factor (HGF) or Wnt signaling factors (Moustakas and
Heldin, 2007; Peinado et al., 2007; De Craene and Berx, 2013;
Wang and Zhou, 2013; Williams et al., 2019).
Non-coding RNAs (ncRNAs) are among intrinsic regulators
of EMT (Zaravinos, 2015). It is increasingly apparent that the
ncRNAs are crucial in normal development and disease, but
its mechanistic mode of action is largely unknown (Liz and
Esteller, 2016). The two major classes of non-coding RNAs are
long non-coding RNA (lncRNAs) and microRNA (miRNAs).
Accumulating evidence suggests that lncRNAs function in a
broad range of cellular processes such as cell growth, survival,
migration, invasion and differentiation (Mercer et al., 2009;
Sun et al., 2013; Di Gesualdo et al., 2014; Fatica and Bozzoni,
2014). LncRNAs are defined by the size of their transcripts
and are longer than 200 nucleotides (nt), with no protein-
coding function (Eades et al., 2014). Unlike microRNAs, lncRNAs
are poorly conserved, but function in a regulatory network
at the transcriptional, post-transcriptional, and translational
level. miRNAs are 22 nt long RNA molecules that regulate
expression post-transcriptionally primarily by binding to three
prime untranslated region (3′UTR) of target genes (Bartel, 2009).
The imprinted DLK1-DIO3 locus located on chromosome
14 contains three paternally expressed protein-coding genes
(DLK1, RTL1, DIO3) and numerous maternally expressed non-
coding genes, including the lncRNA maternally expressed gene 3
(MEG3), and a cluster of over 50 miRNAs (Zhang et al., 2010; Dill
and Naya, 2018; Baulina et al., 2019; Li et al., 2019).
The DLK1-DIO3 locus has been described as an important
contributor to pluripotency and stemness in embryonic stem
cells (ESCs) (Kaneko et al., 2014). It discriminates between
mouse induced pluripotent stem cells (iPCS) and mouse ESCs,
where genes from the locus were strongly repressed in iPSC
clones compared to ES clones (Liu et al., 2010; Stadtfeld et al.,
2010a). Furthermore, activation of maternally expressed genes
from the locus is a strong indicator of the developmental potential
of iPSC (Kang et al., 2009). miRNAs from the DLK1-DIO3
locus have been shown to promote pluripotency by inhibition
of differentiation and stimulation of self-renewal in mouse ES
cells (Moradi et al., 2017) and were found to be increased
in tumor-originating cancer cells from lung adenocarcinoma
(Valdmanis et al., 2015).
MEG3 is a potential tumor suppressor gene in several cancer
types, mainly through the observation that MEG3 expression is
lower in various tumor tissues compared with non-tumor tissues
of the same origin (Sheng et al., 2014; Sun et al., 2014, 2016; Yin
et al., 2015; Chak et al., 2017; Molina-Pinelo et al., 2018). The
tumor suppressor role of MEG3 is ascribed to stabilization of
p53 with inhibition of proliferation and promotion of apoptosis
(Zhang et al., 2003, 2010; Zhou et al., 2007; Wang et al., 2012;
Sun et al., 2016).
MEG3 was reported to positively regulate EMT in lung
(Terashima et al., 2017) and ovarian (Mitra et al., 2017)
cancer. Furthermore, MEG3 has been shown to contribute
to the development of osteosarcoma through increased
migration, invasion and decreased apoptosis (Wang and Kong,
2018). Higher levels of MEG3 were detected in plasma from
colorectal cancer patients compared with non-cancerous controls
(Liu et al., 2019).
D492 is a primary breast epithelial cell line, immortalized
with the E6 and E7 oncogenes from the human papilloma
virus 16 (Gudjonsson et al., 2002). Therefore, the p53 protein,
which mediates the previously described tumor suppressor role
of MEG3, is repressed in this cell line. D492 can generate
both luminal and basal/myoepithelial cells in monolayer and
3D culture, expressing luminal or myoepithelial keratins such
as keratin 19 and keratin 14, respectively. Furthermore, when
D492 cells are co-cultured with endothelial cells, they, can
generate spindle-shaped colonies with EMT phenotype. D492M
(mesenchymal) was established from one such spindle-shaped
colony (Sigurdsson et al., 2011). D492M is a phenotypically
stable EMT cell line. It has lost epithelial markers such
as keratins, E-cadherin and TP63, and gained expression of
mesenchymal markers such as N-cadherin (Sigurdsson et al.,
2011; Hilmarsdottir et al., 2015). D492M has acquired classical
properties of cancer stem cells, such as increased CD44/CD24
ratio, anchorage independent growth, resistance to apoptosis
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and increased migration/invasion (Sigurdsson et al., 2011).
D492 serves as a model for branching morphogenesis and
together D492 and D492M represent a unique EMT model of
isogenic cell lines with an epithelial and mesenchymal phenotype,
respectively (Briem et al., 2019b). The ability of D492 to undergo
mesenchymal transition upon endothelial stimulation makes it a
valuable cell model to study EMT induced by extrinsic factors,
although it is important to note that neither D492 nor D492M
are tumorigenic in mice.
In this study, we describe a new role for the DLK1-DIO3
locus in EMT and phenotypic plasticity of breast cells. Following
EMT in breast epithelial cell lines, expression of the ncRNAs at
the DLK1-DIO3 locus was increased. In addition, MEG3 was
highly expressed in stromal cells in breast tissue and its expression
correlated with decreased survival in breast cancer. Moreover,
increased expression of the ncRNAs at the DLK1-DIO3 locus in a
breast epithelial progenitor cell line promoted cellular plasticity
and induced partial EMT. Collectively, our study provides a
further understanding of the role of the DLK1-DIO3 locus in
cellular phenotype of breast cells and might provide important
insight into novel therapeutic targets aimed at overcoming
heterogeneity and therapy resistance in breast cancer.
MATERIALS AND METHODS
Cell Lines
Both D492 and D492M were cultured in H14 medium, as
described previously (Gudjonsson et al., 2002; Sigurdsson et al.,
2011) in flasks coated with collagen I (Advanced BioMFatrix,
5005-B). HEK-293T cell were cultured in Dulbecco’s Modified
Eagle Medium (DMEM), high glucose, GlutaMAX (TM),
pyruvate (Gibco, 31966), supplemented with 10% Fetal bovine
serum (FBS), penicillin and streptomycin (Gibco, 15140-122).
Primary Human umbilical vein endothelial cells (HUVECs) were
obtained from Landspitali, University Hospital in Reykjavik,
Iceland, (with informed consent, approved by Landspitali Ethical
Committee No. 35/2013), cultured in Endothelial Growth
Medium 2 (EGM2) media (Lonza, CC-3162) supplemented
with growth factors and 5% FBS, further referred to as EGM5
medium as previously described (Sigurdsson et al., 2011). HMLE
(Elenbaas et al., 2001) is epithelial progenitor cell line, from
which was derived mesenchymal cell line HMLEmes after stable
induction of EMT-TF (Mani et al., 2008). HMLE and HMLEmes
were cultured in chemically defined HMLE media, containing
DMEM/F12 with penicillin and streptomycin and growth factors
Insulin (Sigma, I1882) 10 µg/ml, EGF (Peprotech, AF-100-15)
10 ng/ml, Hydrocortisone (Sigma, H0888) 500 ng/ml.
Primary human luminal-epithelial cells (LEP), myoepithelial
cells (MEP), breast endothelial cells (BRENCs) and fibroblast
were isolated from breast reduction mammoplasties (with
informed consent, approved by the Icelandic National Bioethics
Committee VSN-13-057) as previously described (Sigurdsson
et al., 2011) and maintained in chemically defined medium 3
(CDM3) and chemically defined medium 4 (CDM4) as previously
described (Pechoux et al., 1999; Ingthorsson et al., 2010). All cells
were maintained in an incubator with 5% CO2 at 37◦C.
3D Cultures/Mammosphere Assays
3D cultures were carried out in a 48-well plate format (Corning,
353078) in growth factor reduced reconstituted basement
membrane rBM (further referred to as Matrigel, Corning,
354230). 5–10 × 103 cells were seeded in 150 µl of Matrigel per
well. Plate was incubated in 5% CO2 at 37◦C for 15 min to solidify
the Matrigel and then 300 µl of H14 media was added on top. The
cells were grown for 3 weeks and pictures were taken on day 1, 7,
14, and 21. Cell culture media was changed three times per week.
The colonies were quantified at day 14. The total number of cells
was converted into percentage.
For co-culture experiments, 0.5 × 103 of the epithelial cells
were co-cultured with 1× 105 of endothelial cells (HUVECs) and
were resuspended in 150 µl of Matrigel. Plate was incubated in
5% CO2 at 37◦C for 15 min to solidify the Matrigel and then
300 µl EGM5 media was added on top. HUVECs cultured in
Matrigel are viable, however, quiescent, having supporting role
in the epithelial cells’ proliferation. The effect of MEG3 was
quantified by counting all colonies bigger than 100 µm.
Total RNAseq and Analysis of the Data
The gene microarray expression analysis from D492 and D492M
was published previously from our group by Sigurdsson and
colleagues (Sigurdsson et al., 2011) and the total RNA-sequencing
comparing D492 and D492M was published by Halldorsson and
colleagues (Halldorsson et al., 2017).
The RNA was extracted using Tri-Reagent (Thermo Fisher
Scientific, AM9738) from 5 replicates for each cell line.
Whole Transcriptome Sequencing of D492MKD−CTRL and
D492MKD−MEG3 was performed in deCODE genetics (Reykjavik,
Iceland). RNA sequencing reads were mapped to the reference
genome (Ensembl primary assembly, version GRCh38) using
STAR version 2.6.1 (Dobin et al., 2013). The program htseq-
count (Anders et al., 2015) was used to quantify how many
reads match each gene in an annotation file (Ensemble version
GRCh38.96). The data from htseq-count was imported into R (R
Development Core Team, 2015) and differential expression (DE)
analysis on D492MKD−CTRL vs D492KD−MEG3 was performed
using DESeq2 (Love et al., 2014). Prior to DE analysis, genes
with expression less than two reads were discarded. P-values were
corrected for multiple testing using the false discovery rate (FDR)
method. To compare gene expression from D492MKD−CTRL vs
D492MKD−MEG3 a volcano plot was generated. P value cut-off
of 0.05 was applied. Volcano plot over all data (p < 0.05)
was made in R using the EnhancedVolcano package from
BioConductor. The top ten most upregulated and downregulated
genes according log2 fold change were labeled. Gene Set
Enrichment Analysis (GSEA) was applied to identify enrichment
of gene signatures. Comparative analysis was investigated using
the “Hallmark” database. The list of significantly expressed
pathways is presented as a bar plot.
Quantitative RT-PCR Analysis
Total RNA was extracted with Tri-Reagent (Thermo Fisher
Scientific, AM9738). 1 µg of RNA of each sample was reverse
transcribed into complementary DNA (cDNA), using Random
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Hexamers (Thermo Fisher Scientific, N8080127) and SuperScript
IV Reverse Transcriptase (Thermo Fisher Scientific, 18090-
200) kit and subjected to quantitative real time PCR (qRT-
PCR) using Sybr Green dye Luna R© Universal qPCR Master
Mix (NEB, M3003L) or TaqMan probes Luna R© Universal Probe
qPCR Master Mix (NEB, M3004L) according to manufacturer’s
protocol. GAPDH was used as control for gene expression. For
assaying the relative expression of each gene, the 2−11Ct was
determined using an ABI 7500 instrument (Applied Biosystems).
List of Primers
TaqMAN: ZEB1 (Thermo Fisher Scientific, Hs00232783_m1),
ZEB2 (Thermo Fisher Scientific, Hs00207691_m1), SNAI1
(Thermo Fisher Scientific, Hs00195591_m1), SNAI2 (Thermo
Fisher Scientific, Hs00950344_m1), TWIST1 (Thermo
Fisher Scientific, Hs01675818_s1), GAPDH (Thermo Fisher
Scientific, 4326317E).
SYBR Green: KRT14 (IDT, Hs.PT.58.4592110),
KRT19 (IDT,Hs.PT.58.4188708), MEG3 ex 10-11 (IDT,
Hs.PT.58.25190740), GAPDH (IDT, Hs.PT.39a.22214836),
KRT5 (IDT, Hs.PT.58.14446018), TP63 (IDT, Hs.PT.58.2966111),
CDH3 (IDT, Hs.PT.58.39234242).
Small RNAseq
The Microarray of small RNA data was published previously by
our group by Hilmarsdottir and colleagues (Hilmarsdottir et al.,
2015) and the small RNAseq data was published previously by
Briem and colleagues (Briem et al., 2019a).
miRNA qRT PCR
Total RNA was extracted with Tri-Reagent (Thermo Fisher
Scientific, AM9738). The RNA was reverse transcribed
using miRCURY LNA RT Kit (Qiagen, 339340) for cDNA
synthesis reactions, according to manufacturer’s protocol.
Quantitative RT-PCR analysis of miRNAs was performed
using miRCURY LNA SYBR Green PCR Kit (Qiagen, 339346),
according to manufacturer’s protocol. Gene expression levels
were quantified using primers for: hsa-miR-127-3p (Qiagen,
YP00204048), hsa-miR-409-3p (Qiagen, YP00204358), hsa-
miR-411-5p (Qiagen, YP00204531), hsa-miR-493-3p (Qiagen,
YP00204557). Normalization was done with U6 snRNA (Qiagen,
YP00203907). The 2−11Ct was used determined using ABI
7500 instrument (Applied Biosystems) to calculate the relative
expression of each gene.
Allele Specific Expression Analysis
Total RNA was extracted with Tri-Reagent (Thermo Fisher
Scientific, AM9738) and reverse transcription done using
1 µg of DNase I-treated total RNA using random hexamers
(Thermo Fisher Scientific, N8080127) and SuperScript II Reverse
Transcriptase (Thermo Fisher Scientific, 18064022) according
to the manufacturer’s instructions. PCR primers were designed
using Primer3 and Pyrosequencing primers were designed using
PyroMark Assay Design 2.0 (Qiagen). The reverse PCR primer
had a 5′-biotin modification and was HPLC-purified. Primers
were synthesized by IDT 5′-TGGCCTTTTCTTCTCCTGAA,
5′-/5Biosg/TGACACATGGAAAGCACCAT and sequencing
primer 5′-TCCGGGGTTACTGCCCT-3′. Polymerase chain
reactions were performed in 50 µl using 10 ng of diluted cDNA
or 10 ng of DNA, 1 U DreamTaq DNA polymerase (Fermentas,
EP0701), 1X PCR buffer, 200 µM of dNTPs and 0,5 µM of
each PCR primer. The following PCR protocol was used: 94◦C
for 2 min, followed by 50 cycles of 94◦C for 1 min, 60◦C for
1 min, 72◦C for 1 min and 72◦C for 9 min. To check the
quality of the amplification, PCR products were analyzed by
gel electrophoresis. Pyrosequencing were sequenced using the
PyroMark Q24 system (Qiagen), following the manufacturer’s
instructions. For the ASE SNP, DNA and RNA (cDNA) were
pyrosequenced simultaneously. The proportions of individual
alleles for the SNP were obtained using the PyroMark Q24
software version 1.0.10 (Qiagen). Genomic DNA from D492M
was examined to confirm the heterozygosity.
Clinical Cohort
RNA from breast cancer patients (diagnosed in the years
1987–2003) and relevant patient data was obtained from the
Department of Pathology Landspitali – The National University
Hospital of Iceland. Informed consent was obtained from
patients involved in this study according to the national
guidelines. The study was approved by The Icelandic Data
Protection Commission (2001/523 and 2002/463) as well as
the National Bioethics Committee of Iceland (VSN-11-105-
V2). 119 samples were used in the study assigned to the
following subgroup: 33 luminal A, 24 luminal B, 22 Basal, 12
ErbB2, 10 Normal and 18 not classified. cDNA was synthesized
from 2 µg of total RNA using Random Hexamers primers
(Thermo Fisher Scientific, N8080127) and RevertAid First Strand
cDNA Synthesis Kit (Thermo Fisher). MEG3 mRNA expression
level was measured with the previously described qRT-PCR
primers and TBP (Applied Biosystems, 4326322E) was used as
a reference gene.
Western Blot Assay
Cells were washed with cold Phosphate Buffered Saline (PBS)
and lysed in radio immunoprecipitation assay (RIPA) buffer
with phosphatase and protease inhibitors (Halt Protease
Inhibitor Cocktail, Thermo Fisher Scientific, 78430) for 10 min
on ice and scraped with cell scraper. Protein concentration
was measured using Bradford reagent (BioRad, 5000002).
Equal amounts of protein (5–15 µg) were separated on 10%
NuPage Bis-Tris gels (Invitrogen, NP0301PK2) with NuPage
MES running buffer (Thermo Fisher Scientific, NP0002) and
transferred with NuPage Transfer buffer (Thermo Fisher
Scientific, NP0006-1) to polyvinylidene fluoride (PVDF)
membranes Millipore Imobilion-FL transfer membrane,
pore size 0,45 µM (Millipore, IPFL00010). The membranes
were blocked with Odyssey Blocking buffer (TBS) (LiCor,
927-500) and incubated with primary antibodies overnight
at 4◦C. List of antibodies: keratin 14 (KRT14; Abcam,
Ab15461), keratin 19 (KRT19; Abcam, Ab7754), P-cadherin
(CDH3; Cell signaling, CS2130), tumor protein p63 (TP63,
Abcam, Ab124762), keratin 5/6 (KRT5/6; Invitrogen, 180267),
Actin (Licor, 926-42212). Actin was used as loading control.
Secondary antibodies were mouse or rabbit IRDey (Li-Cor
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926-32213, 926-32212, respectively) used at 1:10.000 for 1 h
at room temperature (RT) and detected and quantified using
the Odyssey Infrared Imaging System (Li-Cor Fluorescent
signal was detected by Odyssey image system (Li-Cor) and
converted to gray scale.
Cell Migration Assay
Cell migration was examined by using trans-well Boyden
chambers with 8 µm pore size (Corning, 353097). Briefly, 3× 103
cells were resuspended in 250 µl H14 medium and seeded on
the trans-well inserts in 24-well plate (Corning, 353047). H14
media with 10% FBS was added to the lower chamber, below
filter. Cells were incubated for 48 h in 5% CO2 at 37◦C. Non-
migratory cells from the upper part of the filter were removed
with cotton swab and washed 3 times with 1× PBS. The filters
were then fixed with methanol and stained with DAPI (Sigma,
D9542-1MG). Cells were photographed in three random fields
EVOS FL Auto 2 imaging system (ThermoFisher). Pictures were
analyzed with ImageJ Software.
Low Attachment Assay
Anchorage independent growth was examined using 24-well
ultra-low attachment plates (Corning, 3473). Briefly, D492 and
D492M cells were single cell filtered and 500 cells/well were
seeded into EGM5 media and cultured for 9 days. The growth
of colonies was quantified under the microscope, counting all the
colonies bigger than 40 µm.
Apoptosis Assay
Resistance to chemically induced apoptosis was examined by
inducing the cells with 10 µM camptothecin [CPT, Sigma-
Aldrich, C9911)] in 96-well plate format (Corning, 353072).
and quantified using IncuCyte Caspase-3/7 Reagents (Essen
Bioscience, 4440) on IncuCyte Zoom (Essen Bioscience)
according to the manufacturer’s instructions.
Lentivirus Packaging and Transfection
The packaging of lentiviral expression constructs into
pseudoviral particles, was performed with the psPAX2 (Addgene,
12260) and PMDG.2 (Addgene, 12259) plasmids using Turbofect
(Thermo Fisher Scientific, R05319) in HEK-293T cells. The
supernatant was harvested after 48 and 72 h and filtered through
0,45 µm pore filter. For infection, cells were plated on T25
flasks, so they were 70–80% confluent following day and were
infected with 1 ml of viral particles and 1 ml of fresh media in the
presence of 8 µg/ml polybrene. Lentivirus-transduced cells were
selected with antibiotics or sorted by FACS (Sony SH800), based
on fluorescent dye to obtain stable pool of clones. The altered
expression of MEG3 was determined by qRT-PCR.
The list of lentiviral expression constructs (plasmids) used in
the study and their selection marker (with final concentration in
case of antibiotics): pLenti_sgRNA(MS2)_zeo (Zeocin Invitrogen
4 µl/ml), pLenti_dCas9-VP64_Blast (Blasticidin, 2 µg/ml),
pLenti_dCas9-KRAB_mCherry (mCherry fluorescence), SAM
MS2-P65-HSF1 Plasmids (Hygromycin 1 µl/ml).
CRISPRi/CRISPRa
To perform CRISPRi and CRISPRa, two vectors were used.
First, vector with dCAS9 with effector domain KRAB
(pLenti_dCas9-KRAB_mCherry, Genscript) and VP64
(pLenti_dCas9-VP64_Blast, Genscript) effector domain for
CRISPRi and CRISPRa, respectively, was incorporated, using
lentiviral transfection. Subsequently, vector with designed
gRNA targeting specific site of our gene of interest MEG3 was
incorporated, in second round of lentiviral transfection. In case
of gain of function studies with CRISPRa, one additional helper
plasmid SAM (SAM MS2-P65-HSF1 Plasmids, Genscript) was
used to further increase activation.
The sequence of gRNA for overexpression of MEG3:
Guide 1: GCTCTCCGCCGTCTGCGCTA, the sequence
of gRNA for downregulation of MEG3: Guide 2:
GCGGGTGAGGGATCCTCTCGT, the sequence of gRNA
for negative control: GCTTAGTTACGCGTGGACGA were
cloned into pLenti_sgRNA(MS2)_zeo (Genscript).
Statistical Analysis
Statistical differences of qRT-PCRs (Figures 1E,F, Figures 5A,B,
and Figures 7A–C) and functional assay (Figures 8B–E) between
samples were assessed with unpaired Student t-test. Statistical
differences in Figure 8A was calculated using multiple unpaired
Student t-test per row. Statistical differences of quantifications
of western blots (Figures 7B,C) among samples were assessed
using one-way ordinary ANOVA, followed by Tukey’s multiple
comparison test. Statistical differences in Figure 4A (left) was
calculated using Kruskal Wallis Test (one-way ANOVA on
ranks). Statistical analysis of qRT-PCRs in Figure 2 were assessed
with One-way ANOVA with Dunnett’s multiple comparisons
test. All statistical analyses were performed in GraphPad Prism.
P-values below 0,05 were considered significant (∗p ≤ 0.05;
∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001).
RESULTS
MEG3 Is Highly Expressed in Cell Lines
With a Mesenchymal Phenotype and in
the Stromal Compartment of Breast
Tissue
D492 and D492M are isogenic cell lines with stem cell
and mesenchymal properties, respectively. D492 cells acquire
cuboidal shape in 2D culture, and form branching structures
in 3D culture, akin to terminal duct lobular units (TDLU)
in the breast. In contrast, D492M is elongated and spindle-
shaped in 2D culture and in 3D culture it forms irregular
mesenchymal-like colonies (Figure 1A). We have previously
shown that MIR203a and the MIR200 family are downregulated
in D492M and their expression is essential for the epithelial
phenotype (Hilmarsdottir et al., 2015; Briem et al., 2019a). Of
miRNAs upregulated in D492M, the miRNAs at the DLK1-
DIO3 locus are prominent. A microarray analysis of miRNA
expression demonstrated that 15 of the 25 most highly expressed
miRNAs in D492M compared to D492 belong to the DLK1-DIO3
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FIGURE 1 | The DLK1-DIO3 locus is upregulated in breast epithelial stem cells undergoing EMT. (A) D492 and D492M generate branching and mesenchymal
structures in 3D culture, respectively. In 2D culture, D492 is cuboidal in shape and D492M is more spindle shaped. Scale bar = 100 µm. (B) Majority of the top
upregulated miRNAs in D492M are from the DLK1-DIO3 locus. Microarray heat map showing top 25 upregulated miRNAs in D492M compared to D492. 15 of them
are from the DLK1-DIO3 locus (highlighted in orange). (C) LncRNAs from the DLK1-DIO3 locus are among the most upregulated in D492M. RNAseq data showing
top ten differentially expressed lncRNA, with lncRNAs from DLK1-DIO3 locus (MEG3 and MEG8) highlighted in orange. (D) Schematic figure of the DLK1-DIO3
locus. The DLK1-DIO3 locus is located on chromosome 14 and is imprinted. It contains three paternally expressed protein coding genes (DLK1, RTL1, and DIO3)
and many maternally expressed non-coding genes, among them lncRNAs (MEG3 and MEG8) and over 50 miRNAs, among them MIR127 and MIR493 located in
cluster A and MIR409 and MIR411 located in cluster B and numerous C/D-box-containing small nucleolar RNAs (snoRNAs). DMR – differentially methylated region,
filled circles represent methylated DMRs, and unfilled represent unmethylated DMRs. (E) Upregulation of selected ncRNA from the DLK1-DIO3 locus verified with
qRT-PCR. Graphs showing higher expression of MEG3 in D492M compared to D492 (left) and higher expression of four representative miRNAs (MIR127, MIR493,
MIR409, and MIR411) at the DLK1-DIO3 locus in D492M compared to D492 (right). Results shown as mean ± SD. Unpaired t-test was used to test significance:
**p ≤ 0.01; ***p ≤ 0.001; n = 3. (F) ncRNAs from the DLK1-DIO3 locus are upregulated in HMLEmes. qRT-PCR showing higher expression of MEG3 and
representative miRNAs (MIR127, MIR493, MIR409, and MIR411) from DLK1-DIO3 locus in HMLEmes compared to HMLE. Results shown as mean ± SD. Unpaired
t-test was used to test significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; n = 3.
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FIGURE 2 | The ncRNA from the DLK1-DIO3 locus are highly expressed in stromal cells and whole tissue compared to epithelial cells. qRT-PCR showing MEG3
expression is higher in breast stromal cells (fibroblasts) and whole tissue than in D492 (left). (LEP – luminal epithelial cells, MEP – myoepithelial cells, BRENCs –
breast endothelial cells). Results shown as mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test was used to test significance: **p ≤ 0.01;
****p ≤ 0.0001; n = 3. Expression of representative miRNAs MIR127 and MIR411 at the DLK1-DIO3 locus is higher in breast fibroblast than in D492 (right). LEP –
luminal epithelial cells, MEP - myoepithelial cells. Results shown as mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test was used to test
significance: *p ≤ 0.5; n = 3.
locus (Figure 1B). Furthermore, small RNA sequencing revealed
that 33 of the miRNAs belonging to the DLK1-DIO3 miRNA
cluster have more than 1,5-fold increased expression in D492M
compared to D492 (Supplementary Figure 1). Moreover, total
RNA sequencing of D492 and D492M, revealed that MEG3 and
MEG8 are amongst the most upregulated lncRNAs in D492M
(Figure 1C). The non-coding part of the DLK1-DIO3 locus
consists of maternally expressed lncRNAs MEG3 and MEG8 and
miRNAs grouped into two clusters (Figure 1D). To confirm
the sequencing results, we selected four representative miRNAs
from the DLK1-DIO3 locus, two from each cluster (MIR127
and MIR493 from cluster A, MIR409 and MIR411 from cluster
B). These miRNAs as well as the lncRNA MEG3 had higher
expression, as revealed by qRT-PCR, in D492M compared to
D492 (Figure 1E). In another isogenic EMT cell model, HMLE
(epithelial) and HMLEmes (mesenchymal variant) both MEG3
and the representative miRNAs were more highly expressed in
HMLEmes compared to HMLE (Figure 1F). Thus, our data
suggests that increased MEG3 expression is not a stochastic
event but consistently associates with EMT induction in breast
epithelial cell lines.
Next, we analyzed the expression of MEG3 and miRNAs from
the DLK1-DIO3 locus in primary cells from three healthy donors.
We found that the expression of MEG3 is higher in purified
stromal cells (fibroblasts) than in epithelial cells (D492, luminal
epithelial cells, myoepithelial cells and organoids; Figure 2,
left). Interestingly, expression of MEG3 in whole breast tissue
lysates is closer to fibroblast expression levels than epithelial
cells (Figure 2, left). This finding is most likely explained by the
richness of stroma in normal breast tissue, whereas organoids
contain only the epithelial cells. A similar pattern is seen with the
four representative miRNAs, where MIR127 and MIR411 have
higher expression in fibroblasts compared to their expression in
D492 (Figure 2, right).
We next acquired a list of genes correlated the expression
of MEG3 using the GOBO (Gene expression-based Outcome
for Breast Cancer Online) dataset and submitted the list
to DAVID (the database for annotation, visualization and
integrated discovery, version 6.7) (Huang et al., 2009a,b)
to identify pathways associated with MEG3. Herein, the
expression of MEG3 correlates with expression of extracellular
matrix genes, which are in line with the observations of
a high expression of MEG3 in cells found in the stromal
compartment (Supplementary Figure 2A). Using analysis
of publicly available NGS data using MiPanda (Niknafs
et al., 2018) we found positive correlation of MEG3 with
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common EMT markers in normal breast and breast cancer
(Supplementary Figure 2B). Many of these have a correlation
coefficient > 0.3 (Spearman correlation) which is considered
a fair positive correlation (Chan, 2003). Interestingly, even
more genes are positively correlated to MEG3 expression
in breast cancer as compared to normal breast tissue
(Supplementary Figure 2B).
Collectively, the lncRNA MEG3 and miRNAs from DLK1-
DIO3 locus are highly expressed in the mesenchymal
compartment compared to epithelial breast tissue and their
expression positively correlate with numerous mesenchymal
genes and EMT markers.
MEG3 Is Imprinted in Both D492 and
D492M
The DLK1-DIO3 locus is imprinted and regulated by DNA
methylation (Cui et al., 2018). Using pyrosequencing (Harrington
et al., 2013) covering a heterozygous SNP (C/T) in MEG3
(rs4906024) we confirmed monoallelic expression of MEG3
in both D492 and D492M, with expression in both cell
lines being from the T allele (Figure 3). As both cell lines
are diploid at the MEG3 locus on a DNA level a C/T
ratio of 50% is expected which is consistent with the 48%
C-allele prominence observed. On the mRNA deviation from
expected monoallelic expression was not detected as results
showed zero C allele expression in D492 and 2% in D492M.
Hence, increased expression of MEG3 in D492M is not caused
by loss of imprinting. The expression remains monoallelic
confirming that the increased expression originates from the
non-imprinted allele.
Increased Expression of MEG3 Is
Negatively Correlated With Survival of
Breast Cancer Patients
EMT has been suggested to promote metastatic behavior of
epithelia-originating cancer (Felipe Lima et al., 2016) and,
in addition, our data shows association of MEG3 expression
with the mesenchymal phenotype. We therefore investigated
MEG3 expression levels in different subtypes of breast cancer.
We have evaluated the expression of MEG3 in clinically well-
defined breast tumors. Herein, normal like (NL) breast tumors
had significantly higher expression of MEG3 with a p-value
of 0.0003 (Figure 4A, left). Survival analysis of all tumor
samples showed reduced, but not significant overall survival in
patients with high MEG3 expression. However, as the normal-
like tumors have in recent years been subjected to scrutiny as
a possible misclassification due to low tumor cellularity and
thus, high proportion of normal tissue. In light of our results
showing high expression of MEG3 in breast stromal tissue, and
uncertainty that measured MEG3 expression in the normal-like
subgroup is representative of the primary tumor, we omitted
NL breast tumors from the survival analysis (Elloumi et al.,
2011; Prat and Perou, 2011; Yersal and Barutca, 2014). The
results show significant worse overall survival of patients with
high MEG3 expression (Figure 4A, right). Corroborating our
FIGURE 3 | Increased expression of MEG3 in D492M is not caused by loss of
imprinting. Allele specific expression analysis using pyro-sequencing shows
that the increased expression of MEG3 in D492M is not caused by loss of
imprinting, but increased expression of the already expressed allele, the
expression remains mono-allelic. Analyzed sequence: GAGCAC/TGTCCCA.
findings, using the GOBO database (Ringnér et al., 2011)1, we
found that high MEG3 expression reduces distant metastasis free
1http://co.bmc.lu.se/gobo/
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FIGURE 4 | MEG3 expression negatively correlates with breast cancer prognosis. (A) High MEG3 expression decreases overall survival in breast tumors. qRT-PCR
shows that MEG3 expression (Numbers of tumors per group: ErBB2 = 12, Luminal A = 33, Luminal B = 24, Normal = 10, Basal = 22) is significantly higher in
normal-like (NL) breast cancer (left; p = 0.0003). High MEG3 expression is correlated with low overall patient survival (NL tumors omitted). Kruskal Wallis Test (or
one-way ANOVA on ranks) was used to test the significance (right; p = 0.01). (B) High MEG3 expression decrease distant metastasis free survival in grade three and
Luminal B type tumors. Kaplan-Meier plot showing data from the online GOBO database: high expression of MEG3 decrease DMSF (distant metastasis free
survival), of poorly differentiated (grade 3) tumors (left; p = 0.00373) and luminal B type tumor (right; p = 0.04607).
survival (DMSF) of patients with poorly differentiated (grade 3)
tumors (Figure 4A, left) and patients with luminal B tumors
(Figure 4B, right).
Increased Expression at the DLK1-DIO3
Locus Contributes to the Basal and
Mesenchymal Phenotype
To explore the functional role of MEG3 in D492 and
D492M, we established sublines with altered expression of
MEG3. Using the CRISPRa approach (Cheng et al., 2013),
we generated a D492 cell line with stable overexpression of
MEG3 (D492MEG3). A control cell line was generated using
a scrambled sgRNA (D492CTRL). Furthermore, we used the
CRISPRi approach (Gilbert et al., 2013; Qi et al., 2013), to
generate knockdown of MEG3 in D492M (D492MKD−MEG3)
and a control cell line was generated using scrambled sgRNA
(D492MKD−CTRL). The increase of MEG3 expression was
about seven-fold in D492MEG3 compared to D492CTRL as
determined by qRT-PCR (Figure 5A, left). Downregulation
of MEG3 in D492MKD−MEG3 was more prominent, with
about 20-fold reduced expression compared to D492MKD−CTRL
(Figure 5A, right). Having established stable overexpression and
downregulation of MEG3 in D492 and D492M, we re-evaluated
the epithelial/mesenchymal phenotypes of D492 and D492M,
respectively. Based on phase contrast images, no obvious
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FIGURE 5 | Concomitant expression of non-coding RNAs from DLK-DIO3 locus with MEG3. (A) Overexpression and knock-down of MEG3 in D492 and D492M,
respectively. qRT-PCR confirming upregulation of MEG3 in D492 (D492MEG3) compared to D492 with scrambled control (D492CTRL; left). Phase contrast pictures of
D492CTRL and D492MEG3 (below). qRT-PCR confirming knock-down of MEG3 in D492M (D492MKD−MEG3) compared to D492M with scrambled control
(D492MKD−CTRL; right). Results shown as mean ± SD. Unpaired t-test was used to test significance: ***p ≤ 0.001; ****p ≤ 0.0001; n = 3. Phase contrast pictures of
D492MKD−CTRL and D492MKD−MEG3 (below). Scale bar = 100 µm. (B) miRNAs form the DLK1-DIO3 locus are upregulated with overexpression of MEG3 and
downregulated with knock-down of MEG3. qRT-PCR shows increased expression of four representative miRNAs from the DLK1-DIO3 locus in D492MEG3 compared
to D492CTRL (left) and their decreased expression in D492MKD−MEG3 compared to D492MKD−CTRL (right). Results shown as mean ± SD. Unpaired t-test was used
to test significance: *p ≤ 0.05 **p ≤ 0.01; ****p ≤ 0.0001; n = 3.
difference in phenotype could be seen between D492MEG3 and
D492CTRL or D492MKD−MEG3 and D492MKD−CTRL (Figure 5A,
below). Interestingly, expression of the representative miRNAs
located on the DLK1-DIO3 locus is increased in D492MEG3
compared to D492CTRL, to similar levels as seen in D492M
(Figure 5B, left). Conversely, the expression of representative
miRNAs is downregulated in D492MKD−MEG3 compared to
D492MKD−CTRL (Figure 5B, right). Thus, it appears, that
the expression of miRNAs from the DLK1-DIO3 locus is
concomitant with MEG3 expression. To test, if that holds true,
we used the cBioPortal and explored correlation of MEG3 with
miRNAs using data on invasive breast cancer from the Cancer
Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2012)
we found that of 40 miRNAs that had positive correlation over
0,3 (Person score) with MEG3, 30 were located at the DLK1-DIO3
locus (with other miRNAs from the locus not being in the dataset;
Table 1). This suggests that MEG3 may be used as a marker for the
expression of ncRNAs from the DLK1-DIO3 locus.
Next, we conducted RNA sequencing of our cell lines with
stably altered expression levels of MEG3 focusing on the
analysis of D492MKD−CTRL vs D492MKD−MEG3. There were
1235 significantly differentially expressed genes, with symmetric
distribution over genes downregulated and upregulated in
D492MKD−MEG3, shown in the volcano plot (p < 0.05;
Supplementary Figure 3A), with the list of top 30 up and down-
regulated genes in D492MKD−MEG3 (Supplementary Figure 3B).
To identify unifying biological them from RNA-sequencing
data, we performed Gene Set enrichment analysis (GSEA).
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TABLE 1 | MiRNAs from the DLK1-DIO3 locus positively correlate with
MEG3 expression.





MIR-154/154* Chr14 0.49 7.46E−20 0.44 1.27E−15
MIR-134/134 Chr14 0.48 2.09E−18 0.44 1.22E−15





0.47 4.66E−18 0.47 8.15E−18
MIR-127/3P Chr14 0.46 4.18E−18 0.45 3.89E−16
MIR-136/136 Chr14 0.46 1.08E−16 0.41 2.15E−13
MIR-431/431* Chr14 0.46 7.09E−17 0.39 5.23E−12





0.43 1.14E−14 0.39 2.18E−12
MIR-382/382 Chr14 0.42 1.53E−14 0.41 2.71E−13
MIR-199B/5P Chr9 0.42 2.47E−14 0.40 1.06E−12
MIR-214/214* Chr1 0.42 6.45E−14 0.39 4.35E−12
MIR-409/3P Chr14 0.42 3.41E−14 0.37 3.34E−11
MIR-369/3P Chr14 0.41 1.06E−13 0.37 5.93E−11
MIR-127/5P Chr14 0.41 1.46E−13 0.36 9.70E−16
MIR-495/495 Chr14 0.4 1.07E−12 0.39 3.84E−12
MIR-758/758 Chr14 0.4 3.97E−13 0.36 1.09E−10
MIR-381/381 Chr14 0.39 3.10E−12 0.39 2.80E−12





0.39 3.92E−12 0.37 6.52E−11
MIR-337/3P Chr14 0.39 1.80E−12 0.37 7.17E−11
MIR-493/493* Chr14 0.38 1.15E−11 0.37 2.83E−11
MIR-369/5P Chr14 0.38 1.68E−11 0.33 2.98E−11
MIR-379/379 Chr14 0.37 5.82E−11 0.33 4.49E−09
MIR-370/370 Chr14 0.37 2.51E−11 0.32 1.29E−08
MIR-214/214 Chr1 0.36 1.88E−10 0.35 5.19E−10
MIR-708/708 Chr11 0.35 4.91E−10 0.35 3.60E−10
MIR-432/432 Chr14 0.35 5.39E−10 0.32 1.80E−08
MIR-409/5P Chr14 0.35 3.48E−10 0.31 6.03E−08
MIR-323/3P Chr14 0.35 6.01E−10 0.30 1.65E−07
MIR-376C/376C Chr14 0.34 1.40E−09 0.35 7.42E−10
MIR-889/889 Chr14 0.34 1.57E−09 0.30 1.50E−07
MIR-493/493 Chr14 0.34 1.07E−09 0.29 5.38E−07
MIR-487B/487B Chr14 0.33 7.98E−09 0.30 1.50E−09
MIR-655/655 Chr14 0.33 6.70E−09 0.30 1.90E−07
MIR-410/410 Chr14 0.33 4.36E−09 0.29 5.07E−07
MIR-184/184 Chr15 0.31 3.50E−08 0.34 2.68E−09
MIR-411/411 Chr14 0.31 2.83E−08 0.29 3.79E−07
MIR-654/3P Chr14 0.31 3.64E−08 0.26 4.37E−06
MIR-22/22 Chr17 0.3 1.66E−07 0.29 2.72E−07
Out of 40 miRNAs that positively correlate with MEG3 in breast cancer (with
correlation over 0.3), 30 are from the DLK1-DIO3 locus, highlighted in orange
(TCGA, Nature 2012 data set). #Due to sequence similarities, these two miRNAs
are indistinguishable in the sequencing data used.
These gene sets consist of the defined gene lists, based on
biological knowledge about biochemical pathways and co-
expression data. Using the Hallmark dataset, one of the
significantly, downregulated set of genes in D492MKD−MEG3
was the epithelial-mesenchymal transition gene set, with
normalized enrichment score (NES) of −2.03 and False
discovery rate (FDR) q = 0.023 (Figure 6A). These genes
define epithelial-mesenchymal transition, as in wound healing,
fibrosis and metastasis. The genes belonging to this gene
set are overrepresented toward the top of the ranked list,
based on fold change of D492MKD−CTRL vs D492MKD−MEG3
(Figure 6B, right). A manually curated list of mesenchymal
genes from the Hallmark EMT dataset that are downregulated
in D492MKD−MEG3 is shown in Figure 6B, left. Further
analysis of the RNA sequencing data of D492MKD−MEG3
vs D492MKD−CTRL, using common literature-based markers
of breast tissue has showed that luminal epithelial markers
GATA3 and MUC1 are upregulated, while myoepithelial KRT14,
mesenchymal VIM, ZEB2, SNAI2, LAMA1, CDH2, and stem
cell MME, CTNNB1 are downregulated with knock down of
MEG3 (Figure 6C).
Expression of mesenchymal and basal markers was
additionally confirmed on RNA level by qRT-PCR and on
protein level western blot. Most of the core EMT-related
transcription factors (EMT-TF) were affected by MEG3.
D492MEG3 has increased expression of SNAI2 compared to
D492CTRL (Figure 7A, left). On the other hand, D492MKD−MEG3
has decreased expression of SNAI2, ZEB1, ZEB2 and TWIST1
compared to D492MKD−CTRL (Figure 7A, right). Luminal
cytokeratin 19 (KRT19) and basal/myoepithelial cytokeratin
14 (KRT14) are also affected by manipulation of MEG3
expression levels. Thus, D492MEG3 shows increased KRT14
and decreased KRT19 expression compared to D492CTRL on
both mRNA (Figure 7B, left) and protein level (Figure 7C,
left). D492MKD−MEG3 shows decreased KRT14 expression
compared to D492MKD−CTRL (Figure 7B, right). Furthermore,
D492MEG3 shows increased expression of other myoepithelial
markers such as CDH3 (P-cad), TP63 or KRT5 compared
to D492CTRL as determined both at mRNA (Figure 7D,
left) and protein level (Figure 7E). Also, D492MKD−MEG3
shows decreased expression of myoepithelial markers KRT5
on mRNA level (Figure 7D, right) and of TP63 on protein
level (Figure 7E, middle) compared to D492MKD−CTRL.
This suggests that MEG3 expression induces a shift toward a
basal/myoepithelial phenotype. However, our cell lines with
stably altered expression of MEG3 do not show a significant
switch in E-cadherin (CDH1) to N-cadherin (CDH2) expression
(Supplementary Figure 4), which may explain why there are no
clear changes in morphology.
MEG3 Induces Mesenchymal Properties
and Stemness
As MEG3 has previously been ascribed to have a role in
pluripotency and stemness (Stadtfeld et al., 2010b; Kaneko et al.,
2014), we asked how MEG3 manipulation affects mesenchymal
and stem cell properties of D492 and D492M. The expression of
both aldehyde dehydrogenase (ALDH1A3) and integrin alpha
6 (ITGA6; Supplementary Figure 6), markers of stemness,
is increased in D492MEG3 compared to D492CTRL. Next, we
employed several functional assays to assess the effect of MEG3
levels in D492 and D492M on mesenchymal and stem cell
properties. D492MEG3 is more resistant to chemically induced
apoptosis than D492CTRL (Figure 8A). Migration can be assessed
in vitro using the wound healing assay or by trans-well migration
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FIGURE 6 | Knock down of MEG3 in D492M decrease mesenchymal markers. (A) Epithelial-mesenchymal transition gene set is enriched pathway in
D492MKD−MEG3 (highlighted in orange). Bar plot of Gene Set Enrichment Analysis (GSEA) with Hallmark dataset showing all significantly (False discovery rate-FDR
q ≤ 0.05) enriched pathways in D492MKD−MEG3. Gene set Epithelial-mesenchymal transition has normalized enrichment score (NES) of –2.06 and FDR q = 0.014.
(B) Knock-down of MEG3 correlates with downregulation of mesenchymal genes relevant for breast cells. Enrichment plot showing the Enrichment Score (ES) of the
genes in the Hallmark gene set Epithelial-mesenchymal transition in D492MKD−MEG3. The genes are overrepresented toward the top the ranked list of
D492MKD−MEG3 (right). Table with relevant genes for breast cells, significantly (p ≤ 0.05) deregulated, from the Hallmark gene list epithelial-mesenchymal transition
showing Log2 fold change (FC; left). (C) Luminal epithelial markers (GATA3 and MUC1) are upregulated, while myoepithelial (KRT14), mesenchymal (CDH2, LAMA1,
SNAI2, VIM, and ZEB2) and stem cell (CTNNB1 and MME) are downregulated with knock down of MEG3. Genes from literature-based list of markers significantly
(p ≤ 0.05) differentially expressed in D492MKD−MEG3 vs D492MKD−CTRL.
where the cells migrate toward a chemo-attractant. In the wound
healing assay, D492MEG3 has slightly increased migration rate
compared to D492CTRL, while D492MKD−MEG3 has decreased
migration rate compared to D492MKD−CTRL (Supplementary
Figure 5A). In the trans-well migration assay, D492MEG3
has about two-fold increased migration rate compared to
D492CTRL and D492MKD−MEG3 has reduced migration
rate compared to D492MKD−CTRL (Figure 8B). MEG3
manipulation, however, did not affect invasion in a transwell
invasion assay (Supplementary Figure 5B). We performed
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FIGURE 7 | Continued
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FIGURE 7 | MEG3 induce partial EMT. (A) MEG3 increases expression of EMT transcription factors in D492 and the knock down of MEG3 decrease expression of
TF-EMT in D492M. qRT-PCR showing D492MEG3 increased expression of transcription factors (TF) SNAI2 compared to D492CTRL (left) and decreased expression of
EMT related TF SNAI2, ZEB1, ZEB2 and TWIST1 in D492MKD−MEG3 compared to D492MKD−CTRL (right). Results shown as mean ± SD. Unpaired t-test was used
to test significance: **p ≤ 0.01; ***p ≤ 0.001; n = 3. (B) MEG3 increases expression of myoepithelial marker KRT14 and decrease expression of luminal epithelial
marker KRT19 on mRNA level. qRT-PCR showing D492MEG3 has increased expression of KRT14 and decrease expression of KRT19 compared to D492CTRL (left).
D492MKD−MEG3 has decreased expression of KRT14 compared to D492MKD−CTRL (right). qRT-PCR results shown as mean ± SD. Unpaired t-test was used to test
significance: *p ≤ 0.05; ***p ≤ 0.001; n = 3. (C) qRT-PCR results confirmed on protein level. Representative pictures of western blot (WB) with its quantification
(below). D492MEG3 has increased protein level of KRT14 and decreased protein level of KRT19 compared to D492CTRL. WB results shown as mean ± SD. One-way
ordinary ANOVA, followed by Tukey’s multiple comparison test was used to test significance: **p ≤ 0.01; ***p ≤ 0.001; n = 3. (D) MEG3 increase expression of
myoepithelial markers TP63 and CDH3 and knock-down of MEG3 decrease expression of myoepithelial marker KRT5, on mRNA level. qRT-PCR showing D492MEG3
has increased expression of TP63 and CDH3 compared to D492CTRL (left). D492MKD−MEG3 has decreased expression of KRT5 compared to D492MKD−CTRL (right).
qRT-PCR results shown as mean ± SD. Unpaired t-test was used to test significance: *p ≤ 0.05; **p ≤ 0.01; n = 3. (E) qRT-PCR results confirmed on protein level.
Representative pictures of western blot (WB) with its quantification (below). D492MEG3 has increased protein level of CDH3 (P-cad), TP63 (p63) and KRT5 compared
to D492CTRL. D492MKD−MEG3 has decreased protein level of TP63 compared to D492MKD−CTRL. WB results shown as mean ± SD. One-way ordinary ANOVA,
followed by Tukey’s multiple comparison test was used to test significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; n = 3.
mammosphere assays in rBM (reconstituted basement
membrane, Matrigel) (Figure 8C) and in low attachment
plates (Figure 8D), with comparable results. D492MEG3
increases the formation of colonies compared to D492CTRL
while D492MKD−MEG3 decreases the formation of colonies
compared to D492MKD−CTRL. In addition, we co-cultured
D492MEG3 with endothelial cells (HUVECs) and observed
increased size of colonies and less branching compared to
D492CTRL (Figure 8E). Finally, manipulation of MEG3 levels
slightly affected proliferation rate of D492MKD−MEG3 compared
to D492MKD−CTRL (Supplementary Figure 5C).
DISCUSSION
In this study, we show that ncRNAs from the DLK1-DIO3 locus
are highly expressed in stromal/mesenchymal cells in the breast
and positively correlate with the expression of EMT genes in
breast tissue. MEG3 expression was monoallelic in both D492
and D492M and gain and loss of function studies have shown
concomitant expression of MEG3 with miRNAs from the DLK1-
DIO3 locus, indicating that MEG3 could be used as a marker for
the expression of the non-coding RNAs from the locus. MEG3
expression was shown to be negatively correlated with survival
of breast cancer patients, particularly with the luminal B subtype.
Furthermore, we demonstrate that enhanced MEG3 expression
accompanied by increased expression of the ncRNAs at the
DLK1-DIO3 locus, contributes to partial EMT more correctly
referred to as epithelial plasticity, seen by increased expression
of EMT related TFs, increase of basal/mesenchymal markers and
enhanced properties such as migration, resistance to apoptosis
and clonogenic capacity.
We used an isogenic breast cell line model to study the
expression pattern and functional role of ncRNAs, both miRNAs
and lncRNAs, in EMT. Of interest was the largest miRNA locus
in the human genome and the lncRNA MEG3, both within the
DLK1-DIO3 imprinted region on chromosome 14. The non-
coding part of the DLK1-DIO3 locus has higher expression in
cells with mesenchymal phenotype (D492M) compared to cells
with epithelial phenotype (D492). These results were validated
in primary breast tissue and in another cellular model of EMT.
Furthermore, we have shown that MEG3 expression correlates
with expression of extracellular matrix proteins, which are
secreted by cells with a mesenchymal phenotype, and with
mesenchymal genes in breast tissue. Data from pyrosequencing
demonstrate that the expression of MEG3 is monoallelic in both
D492 and D492M indicating that the increased expression of
MEG3 in D492M is not due to loss of imprinting. We have shown
that MEG3 negatively correlates with survival of luminal B breast
cancer patients and patients with grade 3 breast cancer. This is
in line with a recent study where high expression of MEG3 was
identified to be a negative prognostic marker for breast cancer
(Yao et al., 2019).
Many studies suggest MEG3 as a tumor suppressor, largely
due to the observation that MEG3 expression is lower in
tumor tissue compared to normal tissue (Sheng et al., 2014;
Sun et al., 2014, 2016; Yin et al., 2015; Chak et al., 2017;
Molina-Pinelo et al., 2018). Our data demonstrates that MEG3
expression levels are comparable in whole normal breast tissue
and in stroma (fibroblasts), however, the expression of MEG3 in
epithelial cells is much lower. There was considerable variation
of the MEG3 expression in breast tissue samples that could be
partially due to different proportions of subset of fibroblasts
associated with ducts vs TDLUs. There are studies confirming
existence of, for instance, two distinct functionally specialized
lineages of lobular vs ductal fibroblast (Morsing et al., 2016) or
myoepithelial cells (Fridriksdottir et al., 2017), which could be
identified by specific marker expression. Importantly, relative
proportions of stromal and epithelial compartment are different
in normal and cancerous human breast tissue. Breast cancers
arise in vast majority from epithelial cells, with TDLUs being
the predominant site of breast tumor occurrence (Tabar et al.,
2014). Therefore, it would be expected that expression of MEG3
is higher in normal breast tissue, as it comprises relatively
more stromal cells compared to breast cancer tissue. In line
with this, expression of MEG3 from whole breast tissue is
distorted as proportions of stroma vs epithelia in normal/cancer
tissue are different, resulting in misleading interpretations. Using
RNA only from unsorted normal tissue will mainly represents
expression of stromal cells. Therefore, it is crucial to use a
proper control when comparing expression of genes in normal
vs tumor tissue. Single-cell RNA-sequencing or sorted stromal
and epithelial cells would give more informative results as it
would enable distinctions between epithelial and stromal tissue
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FIGURE 8 | MEG3 increases stem cell properties. (A) MEG3 increase resistance to chemically induced apoptosis. Apoptosis assay: D492MEG3 is more resistant to
chemically induced apoptosis compared to D492CTRL (left). Data is analyzed on Incucyte Zoom and displayed as Caspase 3/7 object count/mm2. Results are shown
as mean ± SD. Multiple unpaired Student t-test per row was used to test significance at 72-h time-point: *p ≤ 0.05; **p ≤ 0.01; n = 6. (B) MEG3 increases
migration and knock down of MEG3 decreases migration through trans-well filters. Migration assay: D492MEG3 has increased migration rate compared to D492CTRL
(left), with representative pictures on side. D492MKD−MEG3 migrates less compared to D492MKD−CTRL (right), with representative pictures on side. Quantification of
number of migratory cells, analyzed using ImageJ software, results shown as mean ± SD. Unpaired t-test was used to test significance: *p ≤ 0.05; ****p ≤ 0.0001;
n = 6. (C) MEG3 increases clonogenic capacity in 3D culture in rBM (reconstitute basement membrane). Mammosphere assay: D492MEG3 has higher clonogenic
capacity compared to D492CTRL (left). D492MKD−MEG3 has lower clonogenic capacity compared to D492MKD−CTRL (right). Data shown as % mean ± SD, *p ≤ 0.05;
**p ≤ 0.01; n = 3. Scale bar = 500 µm. (D) MEG3 increases clonogenic capacity in low attachment assay. D492MEG3 increases the formation of colonies compared
to D492CTRL (left), with representative pictures on side. D492MKD−MEG3 decreases the formation of colonies compared to D492MKD−CTRL (right), with representative
pictures on side. Results shown as % of mean ± SD. Unpaired t-test was used to test significance: *p ≤ 0.05; **p ≤ 0.01; n = 3. Scale bars = 200 µm.
(D) Co-culture of D492MEG3 with endothelial cells (HUVECs) increases number and size of colonies and forms less branching compared to D492CTRL. Results shown
as % of mean ± SD. Unpaired t-test was used to test significance: **p ≤ 0.01; n = 3. Representative pictures scale bars = 200 µm.
compartments. In this paper we show that MEG3 expression
negatively correlates with survival in breast cancer, particularly
in grade three tumors and the luminal B subtype. However,
our study does not determine if the high MEG3 expression
represents increased stromal infiltration in the tumors or elevated
expression in cancer cells.
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Another reason for classifying MEG3 as tumor suppressor
is its action on stabilization of p53 (Ghafouri-Fard and Taheri,
2019). However, inactivation of p53 is a frequent event in cancer,
estimated to have about 50 % occurrence (Gasco et al., 2002;
Marine et al., 2006; Haupt and Haupt, 2017). The percentage is
even higher, when the inactivation in p53’s regulatory pathways
is considered (Joerger and Fersht, 2016). Therefore, the use of
cell lines which lack active p53, such as D492 and D492M, offers
a different approach, more relevant for studying breast cancer
signaling pathways, to study the role of DLK1-DIO3. The role of
p53 in the cell is that of a tumor suppressor, impacting acts in
proliferation, cell cycle and genomic stability (Mercer, 1992). In
D492 cell lines, as could be expected, we did not observe effect on
cell proliferation. Recently, Uroda and colleagues’ stated, that cell
cycle arrest by MEG3 is exclusively p53-dependent, (Uroda et al.,
2019), in line with our suggestions that MEG3 can have a different
role in cells lacking p53. Collectively, these observations could
explain the conflicting results about role of MEG3 in tumors.
Many imprinted genes are located in clusters regulated
by a differentially methylated regions (DMRs) (Bartolomei
and Ferguson-Smith, 2011). In our study targeting the MEG3
promoter, we have observed concomitant expression of MEG3
with other miRNAs from the DLK1-DIO3 locus. Our data may
support previous studies showing that the MEG3 promoter
controls expression of all maternally expressed genes from the
DLK1-DIO3 locus (Tierling et al., 2006; Ioannides et al., 2014;
Sanli et al., 2018). Zhu et al. (2019) have shown that the MEG3-
DMR overlaps with the MEG3 gene promoter and any deletion
in this region inactivates both MEG3-DMR and the MEG3 gene.
Their data shows, that it is the MEG3-DMR, not the MEG3
gene, which regulates imprinting (and expression). Therefore, by
targeting the MEG3 promoter at the MEG3-DMR all the non-
coding RNAs at the DLK1-DIO3 locus are inactivated. MEG3
expression can be considered as a marker for the expression of
other ncRNAs at the locus.
Cellular plasticity, an important contributor to heterogeneity
and drug resistance in breast cancer can be conveyed through
EMT/MET (Liu et al., 2014). Partial EMT (p-EMT) may reflect
cellular plasticity better than full-EMT and consequently, cells
possessing this state adapt more easily to a new environment,
which is necessary for cancer cell invasion and metastasis (Thiery,
2002; Tam and Weinberg, 2013; Lambert et al., 2017). Notably, a
recent report highlights the importance of the intermediate stages
of EMT for the intravasation of tumor cells and for metastasis
formation in experimental breast or skin tumors (Pastushenko
et al., 2018). Similarly, another study showed that cancer cells
might only reach an intermediate EMT stage allowing for
increased motility, while keeping its cellular plasticity (Brabletz
et al., 2018). It has also been observed that full mesenchymal
phenotype (EMT), has a low capacity to form metastasis
compared to p-EMT (Schmidt et al., 2015). The essential
criteria for aggressive behavior does not need to be a particular
phenotype, but rather enhanced cellular plasticity, as is also
observed for hybrid E/M cells (Grosse-Wilde et al., 2015). Thus,
EMT may be viewed as a trans-differentiation process where
epithelial and mesenchymal cells interconvert by passing through
an intermediate “stem-like” state (Grosse-Wilde et al., 2018).
EMT is a complex process and meta-analysis indicates
that there are possibly different types of EMT (Liang et al.,
2016). We have shown, that by manipulating MEG3 expression,
and thus changing the expression of the non-coding genes
at the DLK1-DIO3 locus, the majority of these EMT related
TFs are affected, indicating an important role of the ncRNAs
the DLK1-DIO3 locus in the EMT process. One of the most
typical hallmarks of EMT is downregulation of CDH1 (E-
cadherin) and epithelial-specific keratins (Peinado et al.,
2007). Altered expression of MEG3 does not lead to change
of E-cadherin expression and therefore MEG3 may have
induced only a partial EMT phenotype. However, it has
been shown, that cells with p-EMT phenotype display
concomitant expression of epithelial and mesenchymal
markers (Armstrong et al., 2011) and loss of E-cadherin
is not a prerequisite for EMT (Hollestelle et al., 2013).
Cells undergoing collective migration have hybrid EMT
phenotype characterized by E-cadherin expression, which
helps to maintain cell–cell contacts (Friedl et al., 2012;
Aceto et al., 2015). Furthermore, we have shown that
altered expression of MEG3 revealed distinct luminal and
myoepithelial marker expression. Increased expression of
KRT14 and decreased expression KRT19 indicate increased
myoepithelial differentiation, which has been connected to
a partial EMT phenotype (Petersen et al., 2001). Study on
collective migration revealed KRT14 as a key regulator of
metastasis (Cheung et al., 2016) and the same applied for
collective invasion, which was facilitated by subpopulation
of cells expressing KRT14 (Cheung et al., 2013). The
observed increase of myoepithelial/basal differentiation in
cells with higher expression of MEG3 was supported with
altered expression of other markers such as KRT5, TP63,
and CDH3.
A key characteristic defining breast stem cells is the ability to
form of mammospheres (Dontu et al., 2003; Grosse-Wilde et al.,
2015). Morel and colleagues confirmed that human mammary
epithelial cells undergoing EMT exhibited better mammosphere-
forming capabilities (Morel et al., 2008) and Shimono et al.
have shown that mammosphere-forming activity is abrogated
in both normal and malignant mammary stem cells when the
EMT program is shut down (Shimono et al., 2009). In this
study phenotypic differences upon altered MEG3 expression
were more prominent in 3D than in 2D cell culture, where
MEG3 increased mammosphere formation ability and slightly
decreases branching potential in 3D culture. Furthermore, we
have shown increased expression of ALDH1A3 and ITGA6,
in cells with overexpression of MEG3, supporting role of
MEG3 in stemness.
We propose that increased expression of MEG3, and thus
increased expression of the ncRNAs at the DLK1-DIO3 locus,
in D492 leads to partial EMT phenotype/enhanced plasticity,
seen by molecular changes with increased mesenchymal
and myoepithelial/basal genes and increased migration and
resistance to apoptosis. In contrast, the repression of MEG3,
and the maternally imprinted ncRNAs, in D492M leads to
decreased mesenchymal and basal gene expression and decreased
migration and resistance to apoptosis. Nguyen-Ngoc et al.
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also demonstrated, that motility can occur in cells that retain
an epithelial molecular signature (Nguyen-Ngoc et al., 2012).
This supports our observation, that manipulation of MEG3
expression did not affect the morphological phenotype, but
rather affected the functional phenotype. These characteristic
properties of cells undergoing EMT were originally proposed
to occur in breast cancer by Mani and colleagues (Mani et al.,
2008), showing that stem-like and p-EMT properties share
many characteristics, such as increased migration, resistance
and survival (Creighton et al., 2009; Armstrong et al., 2011;
Hanahan and Weinberg, 2011).
Increased understanding of branching morphogenesis in
the breast and the regulation of EMT and MET may hold
the key for future development of methods and drugs that
neutralize the invading properties of cancer cells. Currently,
there is need for biomarkers to accurately monitor the
EMT/MET process that may improve treatment. Prognostic
value of MEG3 in human malignancies remains controversial
and requires further investigation. Our results and conflicting
data from the literature suggest that MEG3 has a complex role
in breast tissue.
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